Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + gemcitabine + panitumumab
- Development stage
- Phase 2
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of carboplatin (a platinum-based chemotherapy agent), gemcitabine (a nucleoside analog), and panitumumab (a fully human monoclonal antibody targeting EGFR). The combination has been studied in clinical trials for various cancer types, including triple-negative breast cancer, bladder cancer, and biliary tract cancer. In a phase II trial for metastatic triple-negative breast cancer, the combination showed a median progression-free survival of 4.4 months and an objective response rate of 42%, though the results did not support its continued use in this indication. Common adverse effects include rash, fatigue, neutropenia, and thrombocytopenia.
- Other names
- GCaP
02
Targets
Beyond the preview
Go deeper on carboplatin + gemcitabine + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + gemcitabine + panitumumab.